Custom-Made cancer vaccine enters human testing
NCT ID NCT06631079
Summary
This early-stage trial is testing the safety and effects of a personalized oral vaccine called NECVAX-NEO1 when added to standard immunotherapy drugs (anti-PD-1/PD-L1) for patients with solid tumors. The vaccine is custom-made for each patient using markers from their own tumor, aiming to train the immune system to better fight the cancer. The study will enroll about 20 adults whose cancer has either stabilized or progressed after starting standard immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUS Santiago de Compostela
Santiago de Compostela, Spain
-
Charité
Berlin, Germany
-
Comprehensive Cancer Center
Munich, Germany
-
Fundacion Jimenez Diaz
Madrid, Spain
-
Institut Catala d'Oncologia
Barcelona, Spain
-
NCT
Heidelberg, Germany
-
National Cancer Center
Vilnius, Lithuania
-
Vall d'Hebron
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.